Company

Grace Therapeutics, Inc.

GRCE · CIK 0001444192

SEC FORM 4

$11,167.80

Purchase of 5,318 shares at $2.10 per share.

Reporting Person Opaleye Management Inc. · Transaction Code P

Traded Sep 23, 2026 · Disclosed Sep 23, 2026

Source: SEC Form 4 · 0001493152-26-043996 · filed 2026-09-23 · View filing →

SEC FORM 4

$20,519.10

Purchase of 9,771 shares at $2.10 per share.

Reporting Person Opaleye Management Inc. · Transaction Code P

Traded Sep 21, 2026 · Disclosed Sep 23, 2026

Source: SEC Form 4 · 0001493152-26-043996 · filed 2026-09-23 · View filing →

SEC FORM 4CLUSTER · 2 INSIDERS

$245,895.66

Purchase of 115,229 shares across 2 reporting persons.

Transaction Code P · Reporting Persons 2

Opaleye Management Inc.Purchase of 9,393 shares at $2.0972 per share.$19,699.00
Kohli Prashant, Chief Executive OfficerPurchase of 100,000 shares at $2.14 per share.$214,000.00
Opaleye Management Inc.Purchase of 5,836 shares at $2.0899 per share.$12,196.66

Surfaced by rule: 2 distinct insiders, open-market purchases, 7-day window — a deterministic filter, not a recommendation.

Traded Sep 8, 2026 · Disclosed Sep 10, 2026

Source: SEC Form 4 · 0001493152-26-042152 · filed 2026-09-10 · View filing →

Source: SEC Form 4 · 0001140361-26-036125 · filed 2026-09-10 · View filing →

SEC FORM 4

$24,206.16

Purchase of 11,608 shares at $2.0853 per share.

Reporting Person Opaleye Management Inc. · Transaction Code P

Traded Aug 14, 2026 · Disclosed Aug 19, 2026FILED +5 DAYS

Source: SEC Form 4 · 0001493152-26-039124 · filed 2026-08-19 · View filing →